Press Releases

Tuesday, 30 November 2021

Färna Invest Increase Shareholding in Bluefish


Färna Invest and Serendipity Partners have agreed that Färna Invest acquires Serendipity Partners' total shareholding in Bluefish Pharmaceuticals.

“We are very pleased that we were able to increase our shareholding in Bluefish Pharmaceuticals. Our ambition is to prepare Bluefish Pharmaceuticals to be ready for an IPO within the next few years. We will continue to invest further into the company and continue to strengthen Bluefish's European expansion and development of new generic products, ”says Gerald Engström, CEO, Färna Invest.

The company will hold an Extraordinary General Meeting due to changes in ownership, see the company's website for more information.

For more information contact:

Berit Lindholm, CEO, tel. 070-915 41 92

Gunilla Spongh, Chairman of the Board, tel. 070-935 25 33

Gerald Engstöm, CEO of Färna Invest, tel. 070-519 00 01

Bluefish Pharmaceuticals in brief

Founded in Sweden in 2005, with its long tradition of industrial entrepreneurship, Bluefish Pharmaceuticals has become one of the most progressive Swedish pharmaceutical companies for generic products. The company focuses exclusively on development and sale of generic drugs. At Bluefish, we strive to make quality medicines accessible to more people. We create value in the full pharmaceutical value chain from developing to successfully marketing generic pharmaceuticals and we take pride in doing this in an innovative, responsible and cost-efficient way. The product portfolio consists of about 80 products and is growing. Bluefish currently conducts operations in 13 countries in Europe and, over the next few years, will also expand outside Europe with the aim of becoming a global player. The company has its own development laboratory in Bangalore where we develop our own generic products.

For more information, contact

Berit Lindholm, CEO Bluefish Pharmaceuticals 

Tel. 46 8 519 116 00


About Bluefish Pharmaceuticals
Bluefish has undergone significant international expansion since the company was founded in 2005. Bluefish focuses on the development, manufacture and sale of generic pharmaceuticals. The company conducts marketing operations in a large number of European markets and is expanding into territories outside Europe. The product portfolio consists of a total of approximately 80 products and is growing.

Färna lnvest increase shareholding in Bluefish